ResMed Inc.: 10-K Risk Factor Changes

2025 vs 2024  ·  SEC EDGAR  ·  2026-05-22
Other years: 2024 vs 2023 · 2023 vs 2022
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

ResMed substantially restructured its risk disclosures by modifying 21 of 31 total risks, while adding 5 new risks and removing 4 outdated ones, indicating a material refresh of its risk profile. The most significant changes concentrated in three risk categories: core business and industry risks, manufacturing and operational risks, and regulatory compliance risks, suggesting ResMed addressed emerging operational challenges and market dynamics. The addition of securities market risks as a new disclosure category reflects evolving investor-related considerations in the updated filing.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

5
New Risks
4
Removed
21
Modified
1
Unchanged
🟢 New in Current Filing

RESMED INC. AND SUBSIDIARIES

ITEM 1A RISK FACTORS Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described below in addition to the other cautionary statements and risks described elsewhere, and the other information contained in this Report and in our…

Read full text

ITEM 1A RISK FACTORS Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described below in addition to the other cautionary statements and risks described elsewhere, and the other information contained in this Report and in our other filings with the SEC, including our subsequent reports on Forms 10-Q and 8-K. The risks and uncertainties described below are not the only risks we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or uncertainties actually occurs, with material adverse effects on us, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock will likely decline, and you may lose all or part of your investment.

🟢 New in Current Filing RESMED INC. AND SUBSIDIARIES 🔒
🟢 New in Current Filing RESMED INC. AND SUBSIDIARIES 🔒
🟢 New in Current Filing RESMED INC. AND SUBSIDIARIES 🔒
🟢 New in Current Filing Risks Related to the Securities Markets and Ownership of Our Common Stock 🔒
🔴 No Match in Current Filing RESMED INC. AND SUBSIDIARIES 🔒
🔴 No Match in Current Filing Risks Related to Manufacturing, IT Systems, Commercial Operations and Plans for Future Growth 🔒
🔴 No Match in Current Filing RESMED INC. AND SUBSIDIARIES 🔒
🔴 No Match in Current Filing RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified Summary of Risk Factors 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified Risks Related to Our Business and Industry 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified Risks Related to Manufacturing, IT Systems, Commercial Operations and Plans for Future Growth 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified Risks Related to Non-Compliance with Laws, Regulations and Healthcare Industry Shifts 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
🟡 Modified RESMED INC. AND SUBSIDIARIES 🔒
29 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →